SequelSEC

Rallybio Corp RLYB

Pharmaceutical Preparations · CIK 0001739410 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2026-09-30
Operating income
-$3.42M
Fiscal year ended 2026-09-30
Free cash flow
Unavailable
Fiscal year ended 2026-09-30

Valuation, from the filing

Public float$10.60MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$2.00Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue12.4×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity0.2×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Current ratio14.50x89th
SBC / revenue619.3%87th
R&D / revenue2284.0%84th
Operating margin-3853.6%19th
Revenue YoY growth34.9%70th
Net margin-1046.4%30th

Rallybio Corp (RLYB) reported revenue of $0 and net income of -$2.72M for the fiscal year ended 2026-09-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Rallybio Corp’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Rallybio Corp income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-30
Revenue$0$0$212.00K$222.00K$212.00K$212.00K$212.00K$38.00K$299.00K$299.00K
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$3.42M-$5.65M-$8.73M-$6.41M-$6.92M-$10.06M-$9.67M-$11.61M-$12.07M-$17.04M
Net income-$2.72M$43.66M-$8.28M-$5.85M$16.02M-$9.70M-$9.44M-$11.04M-$11.47M-$16.24M
Research & development$584.00K$758.00K$2.87M$3.66M$4.14M$6.07M$5.72M$7.38M$8.24M$12.95M
Weighted-average diluted sharesshares 5.72Mshares 5.80Mshares 5.69MUnavailableshares 5.63Mshares 44.84Mshares 5.60MUnavailableshares 44.59Mshares 44.13M
Pretax income-$2.64M$44.99M-$8.28M-$5.85M$16.02M-$9.42M-$8.85M-$10.61M-$10.83M-$15.75M
Income tax expense$80.00K$1.32MUnavailable$0$0$0UnavailableUnavailableUnavailableUnavailable
Diluted EPS$-0.48$7.53$-1.46Unavailable$2.84$-0.22$-1.69Unavailable$-0.26$-0.37
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$2.84M$4.90M$6.07M$2.98M$2.99M$4.20M$4.16M$4.26M$4.12M$4.39M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Rallybio Corp balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-30
Cash & equivalents$90.69M$92.85M$41.30M$31.37M$32.12M$9.44M$14.78M$13.90M$25.32M$16.67M
Total assets$95.58M$98.06M$54.47M$62.26M$67.66M$51.00M$57.98M$68.11M$79.01M$92.43M
Current assets$94.77M$97.25M$53.49M$61.25M$66.63M$50.26M$57.38M$67.84M$78.23M$91.44M
Total liabilities$3.28M$3.57M$4.20M$4.30M$4.63M$5.04M$3.91M$6.45M$8.19M$12.41M
Current liabilities$3.28M$3.57M$4.14M$4.22M$4.52M$5.04M$3.91M$6.24M$8.19M$12.16M
Total equity incl. NCI$92.30M$94.50M$50.28M$57.96M$63.03M$45.96M$54.07M$61.65M$70.82M$80.02M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$7.00K$833.00K$940.00K$126.00K$269.00K$119.00K$400.00K$278.00K$583.00K$1.22M

Cash flow

Rallybio Corp cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-30
Operating cash flow-$2.28M$45.92M-$7.98M-$4.68M-$6.55M-$8.38M-$10.20M-$9.86M-$13.54M-$10.42M
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flow$0$5.50M$17.90M$3.92M$29.23M$3.04M$11.08M-$1.57M$22.20M$2.60M
Financing cash flow$120.00K$131.00K$3.00K$6.00K$0$10.00K$0$18.00K-$11.00K$5.19M
Net change in cash-$2.16M$51.55M$9.92M-$748.00K$22.68M-$5.33M$876.00K-$11.42M$8.65M-$2.63M
Stock-based compensation$405.00K$424.00K$613.00K$774.00K$1.05M$1.61M$1.88M$1.96M$2.03M$1.92M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$0$2.00K$3.00K$3.00K$35.00K$26.00K$28.00K$30.00K$32.00K$34.00K

Derived

Rallybio Corp derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-30
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailable-4119.3%-2888.3%-3266.5%-4743.9%-4561.3%-30547.4%-4035.5%-5697.3%
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailable289.2%348.6%493.9%761.3%886.3%5165.8%677.9%640.5%
Current ratio28.87x27.26x12.92x14.50x14.74x9.98x14.68x10.87x9.55x7.52x
Revenue YoY growth-100.0%-100.0%0.0%484.2%-29.1%-29.1%UnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailable-3904.7%-2636.0%7554.7%-4576.9%-4452.4%-29063.2%-3834.8%-5430.1%
R&D / revenueUnavailableUnavailable1354.2%1646.4%1954.2%2865.1%2700.5%19434.2%2755.9%4329.8%
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailable2.9%UnavailableUnavailable0.0%UnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open RLYB in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-10-27View SEC filing
10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-13View SEC filing
10-K · Filed 2026-03-16View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-07View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.